AcureOmics qualifies for SME status

AcureOmics AB has been assigned SME (micro, small and medium-sized enterprizes) status by EMEA (European Medicines Agency). AcureOmics is thus eligible to benefit from the provisions for administrative and financial assistance laid down in Regulation (EC) No 2049/2005.

– This is an important first step towards establishing collaborations and gaining access to research networks in the European community, says Jon Gabrielsson, CEO AcureOmics AB.

For further information from the SME Office click here

Download press release

AcureOmics to present at NbiNet meeting October 30 2007, KTH, Stockholm

Written by Administrator

On 30 October, 2007 at KTH, Stockholm, the NbiNet meeting on "Dealing with large data sets and Multivariate analysis i Bioproduction" will take place at KTH, Roslagstullsbacken 21, FB53 Albanova 5th floor, Stockholm.

AcureOmics will present a lecture on "Application of multivariate analysis in bioprocessing" that describe experimental design and multivariate methods in manufacturing.

AcureOmics signs collaboration agreement with Umetrics

AcureOmics AB and Umetrics AB have signed an agreement which opens possibilities for future collaborations that will benefit both companies. The agreement also provides AcureOmics with Umetrics outstanding software for experimental design and multivariate data analysis.

AcureOmics - a new biotech company in the field of personalised medicine

Personalised medicine refers to the use of new analytical methods for molecules to improve the diagnosis and treatment of diseases in patients. The new company based in Umeå will develop methods for personalised medicine. The methods are based on new technologies combined with advanced data analysis.